Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.920EUR

Average target price

9.265EUR

Spread / Average Target

+382.55%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI

Market Cap	47.58M 55.58M 44.4M 40.74M 76.55M 5.32B 78.06M 527M 205M 2.67B 209M 204M 8.82B	P/E 2026 *	-3.1x	P/E 2027 *	-2.91x
Enterprise Value	40.28M 47.05M 37.59M 34.49M 64.8M 4.5B 66.08M 446M 174M 2.26B 177M 173M 7.47B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
08-06	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT

08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
08-06	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news : Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Course Extremes

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	55.58M
ELI LILLY AND COMPANY	+0.94%	+5.52%	+75.43%	+126.39%	1,109B
JOHNSON & JOHNSON	+1.06%	+3.32%	+50.34%	+60.74%	644B
ABBVIE INC.	+0.80%	+5.58%	+25.71%	+75.39%	463B
ROCHE HOLDING AG	-0.17%	+4.14%	+40.88%	+45.42%	371B
NOVARTIS AG	+0.14%	+2.68%	+22.22%	+39.69%	301B
ASTRAZENECA PLC	+0.56%	+5.61%	+0.46%	+13.39%	256B
AMGEN INC.	+1.49%	+4.83%	+47.16%	+66.95%	234B
NOVO NORDISK A/S	+1.26%	+1.26%	-16.20%	-52.68%	205B
GILEAD SCIENCES, INC.	+2.10%	+4.54%	+24.54%	+90.47%	178B
Average	+0.72%	+3.00%	+30.06%	+51.75%	417.9B
Weighted average by Cap.	+0.74%	+3.26%	+43.10%	+71.11%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -26.05M -20.81M -19.09M -35.87M -2.49B -36.58M -247M -96.22M -1.25B -97.79M -95.67M -4.13B	-23.5M -27.45M -21.93M -20.12M -37.81M -2.63B -38.55M -260M -101M -1.32B -103M -101M -4.36B
Net Debt	-7.3M -8.53M -6.81M -6.25M -11.74M -816M -11.97M -80.8M -31.5M -409M -32.01M -31.32M -1.35B	12.3M 14.37M 11.48M 10.53M 19.79M 1.37B 20.18M 136M 53.07M 689M 53.94M 52.77M 2.28B